The global Antidiabetics Market is expected to reach US$ 89.2 billion in 2022, up from US$ 80.4 billion in 2021, with a Y-o-Y growth rate of 10.9%. The industry is expected to reach US$ 223 billion by 2032, with a CAGR of 9.6% between 2022 and 2032. The rising global prevalence of diabetes is expected to be the most significant factor driving the global antidiabetics market from 2022 to 2032.
Also, the development of new products is anticipated to benefit the market in the coming time. . For instance, in January 2022, Novo Nordisk, the Danish drug provider, announced the launch of oral semaglutide in India for the treatment of Type 2 diabetes. Moreover, the development of advanced pumps based on smart technologies such as; AI and ML are predicted to offer various opportunities.
Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14855
For instance, in July 2021, Ypsomed AG expanded the range of features of the mylife YpsoPump system. The app-based deployment of the Dexcom G6 Continuous Glucose Monitoring (CGM) System allows people with diabetes to manage their therapy through their smartphones.
On the contrary, expenses associated with insulin pumps, lack of awareness about the treatment methods, and poor reimbursement framework in developing countries are anticipated to hinder the market growth.
Key Takeaways from the Market Study:
- The insulin segment to record a CAGR of 9.4% by 2032
- The oral segment to witness a CAGR of 9.5% during the forecast period
- Market in the U.S to value US$ 79.6 Billion by 2032· The U.K market to hold a value of US$ 9.2 Billion
- Japan to exhibit a CAGR of 7.9% during the forecast period
- China to secure a market value of US$ 16 Billion by 2032
“Increasing incidences of diabetic patients across the globe and the rising geriatric population are projected to play a vital role in driving the market. Moreover, ongoing R&D is another factor that will benefit the market in the forthcoming period,” says an FMI analyst.
Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-14855
Competition Analysis
- In May 2021, F. Hoffmann-La Roche Ltd., launched mySugar Pump Control under the mySugr app. mySugr Pump Control enables patients to control insulin pumps via smartphone to import and view the data status.
- In May 2022, the Food and Drug Administration approved a new drug for people with Type 2 diabetes. The drug, Tirzepatide is a once-a-week injection that helps people in managing their blood glucose levels and lessen food intake
Key players:
- Bayer Corporation,
- AstraZeneca,
- Boehringer Ingelheim,
- Eli Lilly,
- Bristol-Myers Squibb
Key Segments Profiled in the Global Antidiabetics Market Study
Antidiabetics Market by Product:
- Insulin-based Antidiabetics
- Rapid-Acting Analog
- Long-Acting Analog
- Premixed Insulin
- Short-Acting Analog
- Intermediate-Acting Insulin
- Antidiabetics Drug Class
- Alpha-Glucosidases Inhibitors
- Biguanides
- Sulphonylureas
- GLP-1 (Glucagon-like peptide) Agonists
- DPP-IV (Dipeptidyl Peptidase) Inhibitors
- Meglitinides
- SGLT-II (Sodium-Glucose Transport Proteins) Inhibitors
- Thiazolidinedione
Click here today to buy your full report @ https://www.futuremarketinsights.com/checkout/14855
Antidiabetics Market by Patient Population:
- Antidiabetics for Pediatrics
- Antidiabetics for Adults
- Antidiabetics for Geriatrics
Antidiabetics Market by Route of Administration:
- Antidiabetics Administration through Insulin Syringes/ Insulin Pens
- Antidiabetics Administration through Insulin Pumps
- Intravenous Antidiabetics Infusion
- Oral Antidiabetics Administration
- Other Routes of Antidiabetics Administration
Have a Look at Related Research Reports in the Healthcare Domain:
- https://www.xing.com/discover/detail-activities/6726530035.83d97b
- https://stemfemmes.mn.co/posts/intraocular-lens-market-is-expected-to-reach-a-valuation-of-us-82-billion-by-2032-fmi
- https://janjaonline.mn.co/posts/intraocular-lens-market-is-expected-to-reach-a-valuation-of-us-82-billion-by-2032-fmi
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
